<DOC>
	<DOCNO>NCT01114893</DOCNO>
	<brief_summary>The purpose study determine safety efficacy three concentration travoprost ophthalmic solution ( Groups A , B C ) administer eight time daily .</brief_summary>
	<brief_title>Travoprost Five Day Posology Study</brief_title>
	<detailed_description />
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<criteria>1. either sex race/ethnicity , ≥18 year old 2. diagnose openangle glaucoma , and/or ocular hypertension 3. meet follow IOP entry criterion : Mean IOP ≥ 24 millimeter mercury ( mmHg ) least 1 eye , eye qualify 8 AM Eligibility Visit ( Day 0 ) Day 1 Mean IOP ≤ 36 mmHg eye 8 AM 8 PM Eligibility Visit ( Day 0 ) , 8 AM Day 1 4. satisfies inform consent requirement ; able read , sign date inform consent 1. female childbearing potential meeting protocol condition 2. angle grade less Grade 2 either eye 3. cup disc ratio great 0.8 ( horizontal vertical measurement ) either eye 4. severe central visual field loss either eye 5. abnormality prevent reliable applanation tonometry either eye 6. hypersensitivity prostaglandin analogue component study medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>